The whole plant of Ixeris dentate (IXD) (Asteraceae), a typical Oriental herb, has been used for the treatment of indigestion, pneumonia, hepatitis, contusion and tumor.
The whole plant of Ixeris dentate (IXD) (Asteraceae), a typical Oriental herb, has been used for the treatment of indigestion, pneumonia, hepatitis, contusion and tumor. 1, 2) It has also been used for the treatment of allergic diseases as a folk therapy in Korea. However, it is still unclear by which mechanism this herb inhibits these diseases and how much effect it has on allergic reactions in experimental models.
Mast cells have been thought to play a major role in the development of many physiologic changes during allergic responses.
3) Activation of mast cells, the key cells of allergic inflammatory reactions, occurs in response to a challenge by a specific antigen against which the surface immunoglobulin E (IgE) is directed, or by other IgE-directed ligands. 4) In IgE-mediated activation, a variety of biological substances (products of complement activation, neuropeptides and certain cytokines), chemical agents (compound 48/80, calcium ionophore A23187), drugs (morphine, codeine, desferroxamine) and physical stimuli can elicit the release of mast cell mediators. 5) Mast cell activation, both by IgE-dependent and IgE-independent stimuli, brings about the process of degranulation that results in the fusion of cytoplasmic granule membranes with the plasma membrane. This is accompanied by both the fast external release of granule-associated stored mediators (histamine, neutral proteases, acid hydrolyases, proteoglycans, chemotactic factors, cytokines such as tumor necrosis factor-a (TNF-a) and interleukines, etc.), as well as the generation and release of newly generated mediators, such as products of arachidonic acid metabolism 6) and, at later times, by the production and release of an array of cytokines. 5) Among the preformed and newly synthesized inflammatory substances released on degranulation of mast cells, histamine remains the best-characterized and most potent vasoactive mediator implicated in the acute phase of immediate hypersensitivity. 7) Mast cell degranulation can be elicited by a number of positively charged substances, collectively known as the basic secretagogues of mast cells. 8) The most potent secretagogues include the synthetic compound 48/80 and polymers of basic amino acids. 9) An appropriate amount of compound 48/80 has been used as a direct and convenient reagent to study the mechanism of anaphylactic reactions.
10) The secretory response of mast cells can also be induced by aggregation of their cell surface-specific receptors for IgE by the corresponding antigen. [11] [12] [13] It has been established that the anti-IgE antibody induces passive cutaneous anaphylaxis (PCA) as a typical model for mast cell-dependent immediate type allergic reactions.
In the present study, we showed that IXD inhibited both a compound 48/80-induced anaphylaxis-like fatal response and ear swelling response. We also showed that IXD inhibited anti-dinitrophenyl (DNP) IgE antibody-mediated PCA and compound 48/80-induced histamine release from the rat peritoneal mast cells (RPMCs).
MATERIALS AND METHODS

Materials
Compound 48/80, anti-DNP IgE, DNP-human serum albumin (HSA), o-phthaldialdehyde (OPA), Evans blue, fetal bovine serum, a-minimum essential medium, disodium cromoglycate (DSCG) and metrizamide (density, 1.120 g/ml) were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). The original stock of male ICR mice (4 weeks of age) and male Sprague-Dawley rats (7 weeks of age) were purchased from the Dae-Han Experimental Animal Center (Taejon, Korea), and the animals were maintained at the College of Pharmacy, Wonkwang University. The animals were housed from five to ten per cage in a Compound 48/80-Induced Anaphylaxis-Like Fatal Response Mice were given an i.p. injection of 8 mg/kg of compound 48/80. The IXD was dissolved in saline and administered orally 1 h before the injection of compound 48/80. Mortality was monitored for 1 h after induction of the anaphylaxis-like fatal response.
Ear Swelling Response Compound 48/80 (5 g/l) was freshly dissolved in saline and injected intradermally into the dorsal aspect of a mouse ear using a microsyringe with a 28-gauge hypodermic needle. The thickness of the ears was measured with a digimatic micrometer (Mitutoyo, Japan) under mild anesthesia. Ear swelling response represented the incremental increase in thickness above baseline control values. Ear swelling response was determined 40 min after the injection of compound 48/80 itself, because within a 40-min interval, ear swelling response, evoked by physiologic saline, returned nearly to the baseline thickness.
PCA Reaction An IgE-dependent cutaneous reaction was generated by sensitizing the skin with an i.d. injection of anti-DNP IgE, followed 24 h later with an injection of DNP-HSA into the tail vein of the mouse. The DNP-HSA was diluted in phosphate-buffered saline (PBS). The mice were injected intradermally with 100 ng of anti-DNP IgE into each of two dorsal skin sites that had been shaved 24 h earlier.
The sites were outlined with a water-insoluble red marker.
Twenty-four hours later, each mouse received an injection of 200 ml of the 1 : 1 mixture of 1 mg/ml DNP-HSA in PBS and 4% Evans blue via the tail vein. IXD was administered orally 1 h before the challenge. Forty minutes after the challenge, the mice were killed and the dorsal skin was removed for measurement of the pigment amount of area. The amount of dye was then determined colorimetrically after extraction with 1 ml of 0.1 N KOH and 9 ml of a mixture of acetone and phosphoric acid (5 : 13) based on the method of Katayama et al. 14) The absorbance at 620 nm of the extract was measured in a spectrofluorometer, and the amount of dye was calculated with the standard line of Evans blue.
Preparation of RPMCs RPMCs were isolated as previously described. 15) In brief, rats were anesthetized by ether and injected with 20 ml of Tyrode buffer B (137 mmol/l NaCl, 5.3 mmol/l glucose, 12 mmol/l NaHCO 3 , 2.7 mmol/l KCl, 0.3 mmol/l NaH 2 PO 4 , pH 7.4) containing 0.1% gelatin (Sigma Chemical Co.) into the peritoneal cavity, and the abdomen was gently massaged for about 90 s. The peritoneal cavity was carefully opened and the fluid containing peritoneal cells was aspirated by a Pasteur pipette. Thereafter, the peritoneal cells were sedimented at 150ϫg for 10 min at room temperature and resuspended in Tyrode buffer B. Mast cells were separated from the major components of rat peritoneal cells, i.e. macrophages and small lymphocytes, according to the method described by Yurt et al. 16) In brief, peritoneal cells suspended in 1 ml of Tyrode buffer B were layered on 2 ml of 22.5% w/v metrizamide (density, 1.120 g/ml, Sigma Chemical Co.) and centrifuged at room temperature for 15 min at 400ϫg. The cells remaining at the buffer-metrizamide interface were aspirated and discarded, then the cells in the pellet were washed and resuspended in 1 ml of Tyrode buffer A (10 mmol/l HEPES, 130 mmol/l NaCl, 5 mmol/l KCl, 1.4 mmol/l CaCl 2 , 1 mmol/l MgCl 2 , 5.6 mmol/l glucose, pH 7.4) containing 0.1% bovine serum albu- 5 cells/ml) were pre-incubated for 20 min at 37°C for stabilization before adding IXD. After that, the cells were pre-incubated (15 min) with the IXD, then incubated (10 min) with compound 48/80 (6 mg/ml). The reaction was stopped by cooling the tubes in ice. The cells were separated from the released histamine by centrifugation at 400ϫg for 5 min at 4°C. Residual histamine in the cells was released by disrupting the cells with perchloric acid and centrifugation at 400ϫg for 5 min at 4°C.
Assay of Histamine Release The histamine content was measured by the OPA spectrofluorometric procedure of Shore et al. 17) The fluorescence intensity was measured at 438 nm (excitation at 353 nm) in a spectrofluorometer. The inhibition percentage of histamine release was calculated using the following equation:
Where 'a' is histamine release without IXD and 'b' is histamine release with IXD. 'a' and 'b' can be considered as the amount of histamine expressed by florescence intensity. The spontaneous histamine release value was subtracted.
Statistical Analysis Each datum was represented as the mean and standard error of the mean (S.E.M.) of the different experiments under the same conditions. Dunnett's test was used to make a statistical comparison between the groups. Results with pϽ0.05 were considered statistically significant.
RESULTS
To assess the contribution of IXD in anaphylactic reactions, we first designed an in vivo model of systemic anaphylactic shock reaction. We used compound 48/80 (8 mg/kg) as the inducer of a systemic fatal anaphylaxis-like response. After the injection of compound 48/80, the mice were monitored for 1 h, after which the mortality rate was determined. As shown in Table 1 , the oral administration of 200 ml saline as a control (i.e. compound 48/80 injection without using IXD) proved 100% fatal. When the IXD was orally administered at doses ranging from 0.005 to 0.1 g/kg 1 h before compound 48/80 injection, the mortality was reduced dose-dependently. IXD and DSCG (reference drug) inhibited compound 48/80-induced fatal reaction 75 and 100%, respectively, at the dose of 0.1 g/kg.
We next examined the effect of IXD on the compound 48/80-induced ear swelling response. Previously, we reported that compound 48/80 optimally induced an ear swelling response at the concentration of 100 mg/site.
18) Therefore, in this study, we used 100 mg/site as an optimal concentration of compound 48/80 in subsequent experiments. As shown in Table 2 , when the IXD was orally administrated at doses ranging from 0.01 to 0.1 g/kg 40 min before compound 48/80 injections, the ear swelling response was reduced dose-dependently. The inhibition rate was significant at the doses of 0.05 and 0.1 g/kg. DSCG also showed a marked inhibition rate at the dose of 0.1 g/kg. The number of mice employed in each group was 24 (8/each groupϫ3 independent experiments).
As another way to evaluate the antianaphylactic property of IXD, the effect of PCA was investigated. 19) As described in the experimental procedures, local extravasation is induced by the skin injection of anti-DNP IgE followed by an intravenous antigenic challenge. Anti-DNP IgE was injected into right dorsal skin sites. As a control, the left dorsal skin sites of the mice were injected with saline alone. After 24 h, mice were injected intravenously with DNP-HSA plus Evans blue. The cutaneous reaction can be quantified by measuring the concentration of leaked dye. The oral administration of IXD (0.05, 0.1 g/kg) caused a significant inhibition of the PCA reaction (Table 3) .
The inhibitory effects of IXD on compound 48/80-induced histamine release from RPMCs are shown in Table 4 . IXD Two hundred microliters of saline or IXD was given orally at various doses 1 h before (nϭ8/group) the compound 48/80 injection. The compound 48/80 solution was intraperitoneally given to mice. Mortality (%) was calculated as the No. of dead mice ϫ100/total No. of experimental mice. dose-dependently and significantly inhibited compound 48/ 80-induced histamine release at concentrations from 0.005 to 0.1 g/l. IXD alone did not affect spontaneous histamine release (data not shown). Histamine levels of RPMCs were 12.4 to 23.5 pg/cell. The value of histamine release in the absence of IXD as a control value was determined in each experiment and subtracted. IXD alone only slightly affected spontaneous histamine release.
Finally, we standardized IXD by nuclear magnetic resonance (NMR) spectrometry (Varian Unity 500, 500 MHz, Japan). 20) The water extract of IXD was analyzed by 1 H-NMR spectroscopy of D 2 O solubles. It gave the main biological compound whose signals were overlapped in the 1 H-NMR spectrum of the extract. Especially, chemical shifts were obvious between 4.30 and 5.10 ppm, indicative of dentatins such as sesquiterpene. Stimulation of mast cells with compound 48/80 initiates the activation of a signal-transduction pathway which leads to histamine release. Compound 48/80 increased the permeability of the lipid bilayer membrane by causing a perturbation of the membrane.
23) The membrane permeability increase may be an essential trigger for the release of the mediators from mast cells. This, however, raises the question why does compound 48/80 not induce histamine release from mucosal type mast cells? The present study provided no clue to the answer of this question.
Some studies have shown that compound 48/80 and other polybasic compounds are able to activate G-proteins. 24, 25) More recently, studies have suggested the importance of chloride channels that provide the driving force for calcium influx during mast cell activation. 26) The possible mechanism of these effects appears to be related to the subsequent increase in intracellular cAMP and Ca 2ϩ .
3) Thus, further detailed study is indispensable to the interpretation of our results. It has been clearly revealed that compound 48/80 treatment induces the degranulation of connective tissue mast cells such as peritoneal mast cells, not mucosal mast cells. 27) Thus, the inhibitory effect of IXD against compound 48/80-induced response cannot be applied to mucosal type mast cells.
On the other hand, antigen stimulation of mast cells via the IgE receptor elicits the release of numerous mediators, including histamine in minutes and cytokines in hours. Consequently, these mediators induce immediate or late hypersensitive reactions.
Based on these facts, we carefully assume that IXD might act on the lipid bilayer membrane affecting the prevention of the perturbation being induced by compound 48/80, and regulate the degranulation of the mast cells in mouse skin by stabilizing membrane fluidity. But there is no evidence to support these assumptions in the present study. In order to reveal the mechanism of histamine release inhibition of this prescription, further studies should be performed.
Our results established that IXD might contain compounds with actions that inhibit mast cell-dependent anaphylactic reactions in vivo and in vitro. IXD is known to have some constituents, such as sesquiterpene lacton glycoside, flavonoids, and volatile oils. 21, 22, 28) But no active components for anti-allergic reaction have yet been reported. Although this study showed the 1 H-NMR data, further investigation is necessary to clarify unknown antianaphylactic constituents that may be more active than the IXD extract itself. Also, future work should address the possibility that IXD may also be active in the inhibition of human mast cell degranulation and, therefore, in the treatment of human allergic disorders. 
